Bicistronic Vector Co-Expression for Lysosomal Enzyme Phosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal storage disorders (LSDs) are limited, with only a small number of LSDs having effective therapies, and existing enzyme replacement therapies face challenges in efficiently delivering enzymes to lysosomes due to inefficient phosphorylation processes.
Innovation Solution
The use of a bicistronic vector expressing a lysosomal enzyme and a modified GlcNAc-1 phosphotransferase (S1-S3 PTase) to enhance the phosphorylation of lysosomal enzymes, improving their uptake, distribution, and activity within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat lysosomal storage disorders, then the missing enzyme is supplemented in patients, but the delivery efficiency to lysosomes is insufficient due to inefficient phosphorylation processes
Solution Approach 1:
The patent modifies the phosphorylation process by introducing a modified GlcNAc-1 phosphotransferase with enhanced enzymatic activity. This parameter change in the phosphorylation efficiency directly improves the delivery efficiency of enzymes to lysosomes, resolving the contradiction between therapeutic efficacy and delivery efficiency
Solution Approach 2:
The patent uses a bicistronic vector as an intermediary delivery system that co-delivers both the lysosomal enzyme and the modified phosphotransferase. This intermediary mechanism ensures efficient phosphorylation and subsequent lysosomal targeting, overcoming the delivery efficiency limitation while maintaining therapeutic efficacy
2Productivity
If a vector expresses both lysosomal enzyme and modified phosphotransferase, then phosphorylation is enhanced and lysosomal delivery is improved, but the vector complexity increases
Solution Approach 1:
The patent combines the expression of lysosomal enzyme and modified phosphotransferase into a single bicistronic vector. This merging approach enables coordinated expression of both proteins from one vector construct, improving phosphorylation efficiency while managing vector complexity through integrated design
Solution Approach 2:
The bicistronic vector serves multiple functions: it delivers the lysosomal enzyme, delivers the modified phosphotransferase, and coordinates their expression. This multi-functionality resolves the contradiction by achieving enhanced phosphorylation through a single versatile delivery system rather than multiple separate systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enhanced phosphorylation increases the cellular uptake and lysosomal delivery of enzymes, leading to improved therapeutic efficacy in treating LSDs, including increased tissue distribution and reduced substrate accumulation.
Implementation Method 1
enhance the phosphorylation of lysosomal enzymes, improving their uptake, distribution, and activity within cells
Data Source
AI summary
Provided herein are compositions and methods of using a bicistronic vector for treating or preventing a lysosomal storage disorder (LSD) in a subject. The disclosed compositions comprise a bicistronic vector comprising a promoter, an Internal Ribosome Entry Site (IRES), a polynucleotide encoding a lysosomal enzyme and a polynucleotide encoding a modified GlcNAc-1 phosphotransferase (GlcNAc-1 PTase). The present methods comprise administering to the subject a pharmaceutical composition comprising the bicistronic vector as disclosed herein.